Slide 1: Revolutionizing Aesthetic Medicine: KB301 PEARL-1 Interim Results
August 2024 1 Revolutionizing Aesthetic Medicine KB301 PEARL-1 Interim Results for Dynamic Wrinkles of the Décolleté and Lateral Canthal Lines Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements 2 This presentation, which includes the accompanying oral presentation, contains, and the answers to questions may contain, forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and
Slide 3: Jeune Aesthetics: Wholly Owned Subsidiary of Krystal Biotech, Inc.
Jeune Aesthetics: Wholly Owned Subsidiary of Krystal Biotech, Inc. 3*Jeune holds exclusive license to Krystal’s HSV-1 gene delivery platform for cash pay markets Subsidiary Dedicated to Aesthetics and Cash Pay Markets* Clinical Development Commercial Fully integrated biotech developing portfolio
Slide 4: Jeune's Groundbreaking Skin Rejuvenation Technology
Jeune’s Groundbreaking Skin Rejuvenation Technology 4 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved.
Slide 5: Lead Program KB301 Designed to Increase Type III Collagen Levels in Aging Skin
Lead Program KB301 Designed to Increase Type III Collagen Levels in Aging Skin 5 Cohort 1 – Safety and PK* Cohort 2 – Initial Efficacy** Cohort 2E – Durability*** Cohorts 3 / 4 KB301 Phase 1 Program PEARL-1 KB301 Payload • Type III collagen (COL3) is the second most abundant protein in the skin but
Slide 6: Aesthetic Improvement Reported at All KB301 Treatment Sites in Cohort 2
Aesthetic Improvement Reported at All KB301 Treatment Sites in Cohort 2 6 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. Both low and high dose KB301 generally well tolerated, with evidence of pharmacodynamic effect and aesthetic improvement across injection sites Cohort 2: Exploratory
Slide 7: Durability of at Least Nine Months Observed in Extension Follow Up
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2 Baseline (n=13) Visit 5 (n=13) Visit 6 (n=12) Month 1 (n=13) Month 2 (n=13) Month 3 (n=10) M ea n C ha ng e in S SS fr o m B as el in e Change in Subject Satisfaction Score Lower Cheek High Dose Group Durability of at Least Nine Months Observed in Extension Foll
Slide 8: Indications for Cohorts 3/4 Selected Based on KB301 Profile and Market Demand
Indications for Cohorts 3/4 Selected Based on KB301 Profile and Market Demand 8 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. Cohort 3 Cohort 4 Lateral Canthal Lines at Rest Dynamic Wrinkles of the Décolleté
Slide 9: Cohorts and Interim Data Review
Cohorts 3 and 4 Interim Data Review 9
Slide 10: PEARL-1 Cohort 3 Evaluating KB301 in Lateral Canthal Lines at Rest
Study Population • 13 subjects enrolled and 12 assessed through two month follow up • Assessed subjects: • Median 57 years of age (range = 31 to 68 years), 92% female • Six subjects received high dose KB301 with microneedling treatment • Two subjects received low dose KB301 and five subjects receive
Slide 11: Interim Safety Findings in Lateral Canthal Region
Interim Safety Findings in Lateral Canthal Region Both low and high dose KB301 generally well tolerated with no adverse change in safety profile upon repeat dosing Localized, Related or Possibly Related Adverse Events* Grade 1 Grade 2 Grade 3 Grade 4 Dryness 2 0 0 0 Erosion 0 2 0 0 Itching 6 0 0 0 P
Slide 12: Clear and Clinically Meaningful Improvements in Lateral Canthal Lines
0% 20% 40% 60% 80% 100% One Month Two Month Investigator Assessed 12 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. Clear and Clinically Meaningful Improvements in Lateral Canthal Lines 0% 20% 40% 60% 80% 100% One Month Two Month Subject Assessed +2 Point = (Much) Improved +1 Point = S
Slide 13: Improvements Also Observed Across Multiple Other Skin Attributes
0% 20% 40% 60% 80% 100% One Month Two Month Investigator Assessed 0% 20% 40% 60% 80% 100% One Month Two Month Subject Assessed Crepiness Elasticity Hydration Radiance Texture 13 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. Improvements Also Observed Across Multiple Other Skin Attribu
Slide 14: Lateral Canthal Lines Before and After Images
Lateral Canthal Lines Before and After Images 14Baseline Two Month Follow Up © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved.
Slide 15: Lateral Canthal Lines Before and After Images
Lateral Canthal Lines Before and After Images 15 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. Baseline Two Month Follow Up
Slide 16: PEARL-1 Cohort Evaluating KB301 in Dynamic Wrinkles of the Décolleté
16 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. PEARL-1 Cohort 4 Evaluating KB301 in Dynamic Wrinkles of the Décolleté Study Objective and Design • Multicenter, open-label study evaluating KB301 for the improvement of dynamic wrinkles of the décolleté in adults • Key study objectives
Slide 17: Interim Safety Findings in the Décolleté Region
Interim Safety Findings in the Décolleté Region Localized, Related or Possibly Related Adverse Events* Grade 1 Grade 2 Grade 3 Grade 4 Bumps 14 1 0 0 Burning 1 0 0 0 Discomfort 0 1 0 0 Edema 1 0 0 0 Hypersensitivity 2 0 0 0 Itching 20 5 0 0 Pain 12 3 0 0 Redness 26 5 0 0 Swelling 2 3 0 0 Tenderness
Slide 18: Profound Improvements Increasing With Time in the Décolleté
18 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. Profound Improvements Increasing With Time in the Décolleté Responder No Change or Worse Subject Satisfaction Responder Rate* Dynamic Wrinkles; Two Month Follow Up 0% 20% 40% 60% 80% 100% One Month Two Month Investigator Assessed GAIS R
Slide 19: Again Seeing Improvements Across Multiple Other Skin Attributes
0% 20% 40% 60% 80% 100% One Month Two Month Investigator Assessed 19 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. Again Seeing Improvements Across Multiple Other Skin Attributes GAIS Responder Rates* by Attribute *Defined as GAIS scores of +1 or +2 Additional attributes assessed and
Slide 20: Décolleté Before and After Images
Décolleté Before and After Images 20 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. Baseline Two Month Follow Up
Slide 21: Décolleté Before and After Images
Décolleté Before and After Images 21 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. Baseline Two Month Follow Up
Slide 22: Décolleté Before and After Images
Décolleté Before and After Images 22 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. Baseline Two Month Follow Up
Slide 23: Next Steps and Market Opportunity
Next Steps and Market Opportunity 23
Slide 24: Next Steps for KB301
Next Steps for KB301 24 Select indication for Phase 2 development – completed, décolleté selected Develop KB301-specific scale and assessment tool for patient report outcomes Initiate Phase 2 development – target study start 2025 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved.
Slide 25: No Primary Aesthetic Tool Addresses Aged Skin
No Primary Aesthetic Tool Addresses Aged Skin Fillers: Fat and Bone Loss Neuromodulators: Dynamic Wrinkles NO PRIMARY TOOL Aged Skin © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. 25
Slide 26: Address Root Cause of Skin Aging
Address Root Cause of Skin Aging Injected with Standard Syringes and Needles Shipped and Stored like other Injectables No Capital Equipment Investment Jeune Technology Jeune Technology Jeune Technology Jeune Technology Ideal Primary Tool for Skin Rejuvenation © Copyright 2024 Jeune Aesthetics, Inc.
Slide 27: Significant Existing Consumer Demand
4.5M Aesthetic Injection Consumers Globally1 No FDA Approved Aesthetic Injectables for the Décolleté © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. 1 International Society of Plastic Surgery, Global Survey, 2022. Consumer number calculated from global neurotoxin procedures divided by t
Slide 28: Significant Market Expansion Trends
Significant Market Expansion Trends Growing Skin Rejuvenation Market1 WW Annual Expenditure $24.6B 2023 $44.5B 2030 Increasing Demand due to GLP-1 Accelerated Skin Aging3 Collagen and Elastin Damage in Skin due to Significant Weight loss © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. P
Slide 29: Projected Aesthetic Treatment Ladder
Projected Aesthetic Treatment Ladder © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved. 29 OTC Beauty Lotions Aesthetic Practice Visit Skin Rejuvenation with Jeune Technology Addition of Neurotoxin and Filler
Slide 30: Market Size
Market Size Fillers: Fat and Bone Loss Neuromodulators: Dynamic Wrinkles Aged Skin POTENTIAL MARKET $5B $4B $5B Global filler revenue : https://www.fortunebusinessinsights.com/industry-reports/dermal-fillers-market-100939 Global neuromodulators revenue: AbbVie earnings and Aesthetics Market Resilien
Slide 31: Deep Pipeline Targeting Priority Extracellular Matrix Proteins Including Elastin
Deep Pipeline Targeting Priority Extracellular Matrix Proteins Including Elastin 31 PROGRAM INDICATION PAYLOAD PRE-CLINICAL PHASE 1 PHASE 2 KB301 Dynamic Wrinkles of the Décolleté Type III collagen (COL3) KB303 TBD elastin (ELN) KB304 TBD COL3 + ELN KB302 TBD Type 1 collagen (COL1) KB305 TBD Type IV
Slide 32: Long Term Strategic Vision for Jeune
32 Long Term Strategic Vision for Jeune Vision: Creating a new segment of fundamentally rejuvenative aesthetics built on Krystal’s proprietary gene delivery platform Krystal well-positioned to rapidly advance KB301 through value-creating Phase 2 milestones As KB301 progresses in the clinic, need
Slide 33: Closing: Q&A
\ Closthg ant > Q&A JEUNE